Giulia Massaro

Florence, 50134, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial.

Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial.

Journal: The oncologist

Published: October 07, 2025

NUC-1031 in aBTC: A cautionary tale in accelerated drug development.

NUC-1031 in aBTC: A cautionary tale in accelerated drug development.

Journal: Journal of hepatology

Published: May 11, 2025

Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift.

Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift.

Journal: World journal of gastrointestinal oncology

Published: March 05, 2025

Beneath the surface of colorectal cancer: Unmasking the evolving nature of (Neo)RAS.

Beneath the surface of colorectal cancer: Unmasking the evolving nature of (Neo)RAS.

Journal: Critical reviews in oncology/hematology

Published: October 26, 2024

The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?

The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?

Journal: Critical reviews in oncology/hematology

Published: February 02, 2024

The treatment of advanced melanoma: Current approaches and new challenges.

The treatment of advanced melanoma: Current approaches and new challenges.

Journal: Critical reviews in oncology/hematology

Published: September 30, 2023

Safety and Tolerability of COVID-19 Vaccines in Patients with Cancer: A Single Center Retrospective Analysis.

Safety and Tolerability of COVID-19 Vaccines in Patients with Cancer: A Single Center Retrospective Analysis.

Journal: Vaccines

Published: April 30, 2022

Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study.

Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study.

Journal: Frontiers in oncology

Published: April 11, 2022

Showing 1-8 of 8

Last Updated: 09/26/2026